OTLK · Outlook Therapeutics, Inc. · Exempt Offerings
$0.59
+0.02 (+3.13%)
At close · Oct 2
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 18, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Because our cash and cash equivalents, together with $51.1 million of net proceeds from our August 2026 Offering, will not be adequate to fund our currently planned operations through at least the 12 months from the date of this Quarterly Report, there is substantial doubt about our ability to continue as a going concern.”View the 10-Q filed Aug 18, 2026
Market Cap
$155.68M
Shares
243.45M
Volume · Oct 2
5.62M
Avg daily vol (3M)
13.63M
Private capital raises reported to the SEC on Form D under Regulation D, showing the offering size, amount sold, minimum investment and number of investors. Public operating companies rarely raise capital this way, so this page is often empty.
| Filed | Type | Industry | Offering | Sold | Exemptions |
|---|---|---|---|---|---|
| 2026-05-07 | New | Biotechnology | $5,000,000 | $0 | 06b |
| 2025-01-27 | New | Biotechnology | $31,977,359 | $0 | 06b |
| 2024-04-16 | New | Biotechnology | $13,250,005 | $5,000,002 | 06b |
| 2024-03-29 | New | Biotechnology | $159,000,000 | $60,000,000 | 06b |
| 2023-01-06 | New | Biotechnology | $1,031,510 | $1,031,510 | 06b |
| 2023-01-06 | New | Biotechnology | $31,820,000 | $31,820,000 | 06b |
| 2021-02-12 | New | Biotechnology | $4,013,627 | $4,013,627 | 06b |
| 2020-06-09 | New | Biotechnology | $16,000,000 | $16,000,000 | 06b |
| 2020-03-11 | New | Other | $7,971,155 | $7,971,155 | 06b |
Showing 1–9 of 9 filings
Key facts
CIK
1649989
CUSIP
69012T305
13F (30d)
11 filings
3 filers
Visit website
Investor relations